#6 - Celgene (NYSE:BMY)
Celgene (NASDAQ: CELG) - Biotechnology stocks are not for the faint-hearted investor. However, whether you rode Celgene all the way down to its current level, or are looking for a stock that’s likely to rise in 2019, Celgene looks like a good bet. This is a company that churns out an exceptional profit with high margins. Yet somehow it’s been caught up in the correction – which historically hits healthcare, and specifically biotech companies hard. A common critique of the stock is that it relies on its multiple myeloma drug Revlimid for approximately 60% of sales. However, despite noise about generic competitors eating into sales, the company has reached settlements which will make Revlimid the only game in town until January of 2026. That’s a long time for the drug to help CELG continue to deliver profits. But with biotech companies, the story is always about what’s coming down the pipeline. In the case of Celgene, the future looks very promising with reports indicating that the company and its partners are working on what could be first-in-class medicines for cancer, inflammation and immunology compounds. The company continues to stand by its forecast of earnings per share over $12 in 2020 (currently they are at $3.93). Even if that comes in 10% below forecast, it would still be more than double current levels.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More - Current Price
- $58.87
- Consensus Rating
- Hold
- Ratings Breakdown
- 4 Buy Ratings, 14 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $54.07 (8.2% Downside)
